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ABSTRACT
A rapid and accurate assay for the determination of roxatidine, a selective H 2-receptor blocker, in human plasma was developed.
Analysis was performed by high-performance liquid chromatography (HPLC) with ultraviolet (UV) detector. Roxatidine acetate,
a prodrug of roxatidine, is metabolized rapidly to roxatidine following oral administration. Roxatidine and the internal standard
(ranitidine) were extracted from plasma by solid-phase extraction. The mobile phase of HPLC was consisted of 20 mM KH 2PO4
(pH 7.0) and acetonitrile (5:1, v/v). The calibration curve for roxatidine was linear over the range of 5 to 1000 ng/mL. The precision
and accuracy of within- and between-run were within 10% for roxatidine. The recovery of roxatidine was over 87% for both low
and high concentrations (15 and 500 ng/mL) and the lower limit of quantitation (LLOQ) was 5 ng/mL. The method was successfully
applied to a pilot pharmacokinetic study of roxatidine in healthy subjects.
Key words: HPLC, roxatidine, solid-phase extraction

INTRODUCTION
Upper gastrointestinal (GI) bleeding is one of the
most common medical emergencies. Acute upper GI
hemorrhage results in hospitalization of over 300,000
patients annually in the United States (1). Among the
upper GI bleeders, peptic ulcer is the source in more than
50%(2). Therefore, efficient prevention of peptic ulcer
will be an important issue. The description of selective
H 2-receptor blockade is a landmark in the treatment of
acid-peptic disease (3). Roxatidine, a selective histamine
H 2-antagonist, has a 3-6 times higher antisecretory potency than cimetidine, and about twice that of ranitidine (47)
. It acts by blocking the H 2-receptor on gastric parietal
cells, thus antagonizing the normal stimulatory effect of
endogenous histamine on gastric acid secretion(8).
Roxatidine acetate, a prodrug of roxatidine (9) (Figure
1), following oral administration, is metabolized rapidly
by esterases in small intestine, liver and serum to its active
deacetylated metabolite, roxatidine (10). Roxatidine acetate
is almost completely (93-95%) absorbed after oral administration. The major disposition of roxatidine is via kidney
(95% of renal excretion). Elimination half-life of roxatidine following oral administration is around 4 to 8 hr (11).
Despite the fact that roxatidine acetate has more
* Author for correspondence. Tel: +886-2-8792-4867;
Fax: +886-2-8792-4859; E-mail: paolh@ndmctsgh.edu.tw

potency, it is also demonstrated to have fewer side effects.
For instance, it has no antiandrogenic activity, and does
not have any significant effect on hypothalamic-pituitarygonadal or hypothalamic-adrenal function. Moreover,
roxatidine acetate does not interfere with the elimination
of drugs that undergo hepatic metabolism so that it causes
less drug-drug interaction than cimetidine does (12).
Since roxatidine acetate is more potent and safer
according to some animal studies and clinical trials, it is
important to have a rapid and sensitive analytical assay
to accurately determine the concentration of roxatidine in
plasma samples. Gas chromatography was the most used
method to analyze roxatidine in the past (13), and recently,
a LC/MS(14) method was developed. Though these two
analytical methods are robust and sensitive, the instrumentation is hard to access. Therefore, an accurate,
sensitive and validated high-performance liquid chromatography was set up to determine the roxatidine plasma
level and applied to pharmacokinetic studies of roxatidine in human.
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Figure 1. Structural formula of roxatidine acetate.
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MATERIALS AND METHODS
I. Chemicals
The roxatidine standard with a purity of 99.5%
was kindly provided by Sanofi-Aventis. Ranitidine was
purchased from Sigma-Aldrich and used as an internal
standard. Acetonitrile (ACN) and Methanol (MeOH),
both HPLC grades, were from Merck KgaA (Darmstadt,
Germany). Twenty five percent ammonia solution (Pro.
Analytical grade E) and potassium dihydrogen phosphate
(KH 2PO 4) were also from Merck KgaA (Darmstadt,
Germany). Triethylamine (TEA) of analytical grade
was purchased from Riedel-deHaen®. Drug-free human
plasma used in this study was obtained from Tri-Service
General Hospital (Taipei, Taiwan) and stored at -80°C
until use. Milli-Q water was used throughout this study.
II. Chromatography
The HPLC system consisted of a pump (SHIMADZU LC-10ADVP, Japan), an autosampler (SHIMADZU
SIL-10 ADVP, Japan), an UV detector (SHIMADZU
SPD-6AV, Japan) and a column oven (SHIMADZU CTO10ADVP, Japan). The octadecyl (C18) disposable extraction column (Bakerbond speTM ) was used. The chromatographic separation was performed on a Nova-Pak ® C18
column (150 mm × 3.9 mm, 4 μm particle size, Waters)
at 40°C in a column oven. The mobile phase consisting
of 20 mM KH 2PO 4 (pH 7.0) and ACN (5:1, v/v) was used.
The flow rate was set at 0.8 mL/min. The UV detector
was set at 198 nm and the autosampler was maintained
at room temperature. Sample volume injected was 50 μL
and the run time was set at 8 min.
III. Sample Preparation
Plasma samples were obtained from subjects’
blood by centrifugation at 4°C. Then 100 μL of 10 μg/
mL ranitidine solution as internal standard was added
into 1 mL of plasma sample. Solid-phase extraction
was conducted using octadecyl (C18) disposable extraction cartridges conditioned with 1 mL of methanol and
1 mL of H 2O. One milliliter of plasma sample was then
loaded. The loaded cartridges were washed once with
1mL of H 2O followed by twice with 1 mL of 5% MeOH 0.1% NH4OH (pH 10) and once with 1 mL of 40% MeOH
- 0.1% NH4OH (pH 10). Roxatidine was then eluted from
the column with 1 mL of MeOH. The eluates were evaporated to dryness under N2 stream, reconstituted with
100 μL of mobile phase and vortexed for 30 sec. Finally,
the sample was transferred to the autosampler vial and 50
μL was injected into HPLC.
IV. Calibration Graphs
Roxatidine standard stock or working solutions and

internal standard (ranitidine) stock solution were all
prepared in 10% ACN and stored at 4°C. The concentrations of the standard working solutions for the calibration were from 5 to 1000 ng/mL. One hundred microliter
of 10 μg/mL internal standard solution was added into 1
mL of plasma where 0.1 mL of standard working solution
was included. Quality control (QC) samples at 4 levels
of 5, 15, 500, and 900 ng/mL were prepared and analyzed
to monitor the calibration. Sample extraction and HPLC
analysis were carried out as described above.
V. Validation
The method validation assays were performed following the currently accepted US Food and Drug Administration (FDA) Bioanalytical Method Validation Guidance (15).
The following parameters were determined for the validation of the analytical method developed for roxatidine in
human plasma: linearity, range, precision, accuracy, lower
limit of quantitation, recovery and stability.
For linearity, a line (Y = a + bX) was fitted through
the standard curve ranged by a weighted linear regression
(weight = 1/x 2) of peak height ratio (Y) vs. concentration
(X). The equation Y = a + bX was used to calculate the
concentration of roxatidine in plasma from peak height
ratio obtained by HPLC.
The within-run precision and accuracy were determined by analyzing a set of QC samples (n = 6) at each of
the four levels, 5, 15, 500, 900 ng/mL. The between-run
precision and accuracy (n = 6) were also carried out by
analyzing QC samples at the above four concentrations.
The precision of the assay for roxatidine was evaluated
by the coefficient of variation (CV) and the accuracy was
evaluated by the relative error {(mean calculated concentration-concentration spiked) × 100% / concentration
spiked}.
The lower limit of quantitation (LLOQ) is defined in
the presented study as the lowest plasma concentration in
the calibration curve that can be measured with precision
and accuracy.
The relative recovery for roxatidine in human plasma
was determined by comparing the mean peak height
ratios of plasma samples spiked with various concentrations of roxatidine (15 and 500 ng/mL) to solvent samples
and extracted as described (roxatidine in solvent without
extraction) (n = 3).
The stability assays in this study, including freeze
and thaw, benchtop, long-term and working solution,
were conducted in concentrations of 15 and 500 ng/
mL. Freeze and thaw stability for roxatidine in plasma
samples was studied in 3 cycles by frosting and defrosting the samples in 3 replicates. Benchtop stability for
roxatidine in plasma samples was studied in triplicate at
0, 4, and 12 hr prior to processing. Long term stability
for roxatidine in plasma samples was studied in triplicate
at 0, 15, 30, 60, and 90 days prior to processing. Working solution stability for roxatidine was studied with 150
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ng/mL and 5000 ng/mL at 0 and 6 hr at ambient temperature. QC samples were prepared at three concentrations,
low (15 ng/mL), medium (500 ng/mL) and high (900 ng/
mL), before assayed and analyzed routinely with clinical samples to monitor the performance of the assay. All
QC sample concentrations were assayed and interpolated
from the concentration standard curve to evaluate the
precision and accuracy.
VI. Pilot Pharmacokinetic Study
The pharmacokinetic study was approved by the
Institutional Review Board (IRB) of Tri-Service General Hospital. All the volunteers were signed informed
consent prior to participating in this study. Three
healthy volunteers aged of 25, 27 and 28 were selected
for the pilot pharmacokinetic study. All three subjects
underwent an overnight fasting before the treatment. A
regimen of 150 mg controlled-release roxatidine acetate
capsule (Roxane ® 75 mg/cap) was administered orally by
the subjects once daily for 7 days. Each dose was administered with 240 mL of water and no food or fluid (except
water) was permitted 4 hr after administration. Blood
samples were collected on days 5, 6 and 7 just prior
to daily dose. On day 7, blood was drawn at 0.25, 0.5,
0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, and 24 hr. All the
plasma samples were stored at -80°C before analysis.

RESULTS AND DISCUSSION

II. Linearity, Accuracy, and Precision
The linear response of calibration curve was
observed over the range of 5-1000 ng/mL with correlation coefficients of at least 0.995. The mean peak height
ratio vs. concentration of roxatidine curve was shown
in Figure 3, and the quality control samples of betweenand within-run data was shown in Table 1. LLOQ was 5
ng/mL, which can be measured with precision and accuracy. The precisions were 5.9% and 7.5% and the accuracies were 101.3 and 107.7 for within- and between-run
validation, respectively (Table 1). As shown in Table 1,
the CVs and relative errors of within-run were less than
5.9% and ranged from -4.7 to +3.2%, respectively. For
between-run, CVs and relative errors were less than
7.5% and ranged from +1.4 to +7.7%, respectively. These
results indicated that the method was precise and accurate within the analytical range.
III. Recovery

I. Chromatography
Representative HPLC chromatograms of drug-free
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plasma and plasma sample spiked with 5 ng/mL roxatidine and 1000 ng/mL ranitidine are shown in Figure 2A
and 2B, respectively.
The retention time for rantidine and roxatidine was
3.5 and 7.7 min, respectively. No significant interfering
peaks were observed at the retention time of roxatidine
and the internal standard of blank plasma due to endogenous compounds or reagents. These chromatograms
indicated that roxatidine and internal standard could be
resolved from the rest endogenous substances.
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Figure 2. Representative chromatograms obtained from (A) drug-free human plasma and (B) human plasma spiked with roxatidine (5 ng/mL)
and ranitidine (1000 ng/mL).
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Figure 3. A peak height ratio-concentration curve of roxatidine at
concentration ranging 5-1000 ng/mL (n = 6). Y= -0.000946 + 0.00363
X, r = 0.998 (weight by 1/x 2).

Figure 4. Concentration - time profile of 3 subjects taken 150 mg of
Roxane® 75 mg/cap orally QD for 7 days.

Table 1. Quality control of within- and between- run (n = 6) for roxatidine calibration standards in human plasma determined by the HPLC
Within-run

Between-run

Known Conc. (ng/mL)

Conc. found (ng/mL)

CV (%)

Error (%)

Conc. found (ng/mL)

CV (%)

Error (%)

5

5.1 ± 0.3

5.9

1.3

5.4 ± 0.4

7.5

7.7

15

15.5 ± 0.5

3.2

3.2

15.2 ± 0.6

3.9

1.4

500

476.3 ± 8.4

1.8

-4.7

532.4 ± 36.6

6.9

6.5

900

897.8 ± 9.7

1.1

-0.2

962.4 ± 46.7

4.9

6.9

Results are expressed as mean ± S.D.

licate were extracted and injected into HPLC. The relative recovery was 92.3% and 87.8% for 15 and 500 ng/
mL, respectively.
IV. Stability
The stability tests of roxatidine in plasma samples
including freeze and thaw, benchtop, long-term and
working solution were all determined by evaluating
the relative errors. The results for the freeze and thaw
stability as well as for the benchtop stability were within
10%, indicating that roxatidine was stable in multiple
freeze and thaw cycles and was stable for at least 12 hr
at ambient temperature. Moreover, the relative errors of
working solution and long term stability at high concentration (500 ng/mL) and low concentration (15 ng/mL)
were within 3%, 15% and 20%, respectively; the results
showed that roxatidine in plasma samples was not only
stable for at least 90 days at -80°C but also for at least 6
hr at ambient temperature.
V. Pilot Pharmacokinetic Study
This precise and accurate HPLC method was applied
to a pilot pharmacokinetic study and yield satisfacto-

ry results for the determination of roxatidine in human
plasma samples following multiple oral administration.
The plasma concentration-time profile of roxatidine at
steady state followed by a regimen of 150 mg Roxane ®
(75 mg/cap) orally QD for 7 days is shown in Figure 4.
The results indicated that plasma level of roxatidine
would reach steady state after 4 days regimen, which was
consistent with literature reported(16). The mean trough
concentration at day 7 was 34.07 ng/mL. Roxatidine was
converted from the prodrug rapidly and reached to maximum plasma concentration (Cmax) of 583.13 ± 16.82 ng/
mL at 1.83 ± 0.29 hr (Tmax). The mean area under the
curve (AUC) of roxatidine was 4968.3 ± 601.18 ng • hr/
mL. The trough concentration and AUC were similar to
those described previously by Lassman, H.B. et al. (30.9
± 10.67 ng/mL and 4362.9 ± 757.18 ng • hr/mL, respectiverly)(16). However, Cmax was higher and Tmax was shorter than their study (435.6 ± 106.5 ng/mL and 3.1 ± 0.55 hr,
respectively), which implied that the absorption of roxatidine in Chinese might be faster than Caucasian.

CONCLUSIONS
The presented study describes and validates a HPLC
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method for the determination of roxatidine in human
plasma. The method proved to be linear in the concentration range studied (5-1000 ng/mL) as well as accurate,
precise and selective. This method of analysis demonstrated that the roxatidine can be successfully used in
human plasma for clinical studies, which indicated that
it could apply to pharmacokinetic, bioavailability and
bioequivalent studies.
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